Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The incidence of melanoma has been increasing faster than that of any other cancer in the United States.
Early detection of melanoma is critical for better patient survival.
Many early melanomas can be recognized with the help of the ABCDEs, and new evolving techniques using complex computer algorithms will augment the effectiveness of early diagnosis.
Public and professional education, regular full-body skin examination by the clinician, and self-examination of the skin are vitally important public health components for reducing deaths from melanoma.
Melanoma is an increasingly important public health problem in the United States and worldwide. The incidence of melanoma has been increasing faster than that of any other cancer in the United States. US invasive melanoma incidence increased 3.1% (p<0.001) annually from 1992. Statistically significant increases are occurring for all histologic subtypes and thicknesses, including those greater than 4 mm. Invasive melanoma currently is the fifth most common cancer in men and the seventh most frequently found cancer in women in the US. A total of 68,180 newly diagnosed cases of invasive melanoma and 46,770 cases of in-situ melanoma were expected in 2010. At current rates, the lifetime risk of an American developing invasive melanoma is 1 in 59 overall and 1 in 37 for Caucasian men and 1 in 56 for Caucasian women. This contrasts dramatically with a lifetime risk of 1 in 1500 for Americans born in 1935. Melanoma is also the most fatal of skin cancers, accounting for 79% of all skin cancer deaths.
The importance of diagnosing melanoma early in its evolution cannot be understated. Since prognosis in melanoma is directly proportional to the depth of the neoplasm, detection of melanoma early in its evolution is of critical importance in saving lives. Melanoma initially grows horizontally within the epidermis (melanoma in situ). In time, it then penetrates into the dermis (‘invasive melanoma’). The vertical depth of the melanoma (measured downward from stratum granulosum) has been shown in multivariate analyses to be the factor that best correlates with prognosis. Therefore, more accurate and effective early diagnosis leading to earlier treatment is critical to successful management.
Fortunately, there has been steady improvement in melanoma survival over decades, with the 5-year survival for invasive melanoma rising from 82% in 1979 to 92% in 2002. Since the primary treatment modality of cutaneous melanoma, surgical excision, has not changed substantially over the past several decades, the improved 5-year survival rate can be primarily attributed to earlier detection.
Earlier detection and therapy also leads to decreased cost of therapy. An estimated 90% of costs spent on melanoma therapy in the US are related to those with advanced disease. Therefore, a significant saving in healthcare cost can be realized if melanoma can be detected in an earlier, more easily treatable phase.
The standard method to evaluate a skin growth to rule out melanoma is biopsy followed by histopathological examination. The challenge lies in identifying the appropriate ‘spot(s)’ on patients who have multiple lesions that have the highest probability for being melanoma. Such lesions should be biopsied and their histopathology appropriately evaluated at the earliest possible time in their evolution. Through education of both healthcare professionals and the lay public as to methods of identifying melanoma, routine physician-driven total cutaneous examinations, and through the teaching of patient self-examination, physicians can play a significant role in reducing deaths from melanoma.
A century ago, melanoma was often not diagnosed until metastatic disease was present. However, diagnostic accuracy has significantly improved over the past 30 years where there has been a significant evolution in the diagnosis of early melanoma ( Table 25.1 ). Several factors have contributed to a marked improvement in detection of cutaneous melanomas at an early, curable stage. Prior to the 1980s, there had been little change in identifying melanoma as the diagnosis was made by identifying gross clinical features. Melanomas were often recognized only when they were large, ulcerated and fungating (see Chapter 24 for clinical presentations). By that time, prognosis was poor. Overall melanoma incidence and mortality continued to increase in the United States and elsewhere, making the early recognition of melanoma a critical public health priority.
Years | Diagnostic Features | Factors |
---|---|---|
1960–70s | Gross symptoms | Bleeding, ulceration |
1980s | Clinical | ABCDs |
1990s | Subsurface | Dermoscopy |
2000s | Digital | Computer-aided analysis |
The goal for every clinician involved in melanoma diagnosis is to strive to increase the ability to detect melanoma at the earliest stage in its development and to promptly remove it. Historically, there are much data to support the fact that melanomas early in their development (in situ or very thin lesions) have an excellent prognosis. Alexander Breslow in 1970 was the first to show that metastases generally did not occur in lesions <0.76 mm in thickness. The fact that early melanomas have excellent prognoses has been repeatedly confirmed by many investigators.
In order for the clinician to make a clinical diagnosis of a possible melanoma, he/she must have a high index of suspicion for melanoma and a thorough knowledge of:
the clinical features of early melanomas ( Chapter 24 )
the clinical features of common pigmented lesions that must be differentiated from melanoma
the characteristics and clinical features of variants of clinically atypical melanocytic nevi (i.e. dysplastic nevi) which may be more commonly seen in association with a higher risk for and/or together with melanoma ( Chapters 22 and 23 )
other factors that increase the risk for a patient developing melanoma: e.g. personal and/or family history of melanoma, history of other non-melanoma skin cancer, presence of dysplastic nevi, presence of many (>100) melanocytic nevi, intermittent sun exposure and sunburn history, history of tanning-booth exposure, especially in childhood/adolescence, red/blonde hair, light eyes, fair complexion, freckling, etc ( Chapters 5 and 6 ).
In 1985, recognizing the critical need to educate physicians and the lay public to recognize melanoma in its early clinical presentation, our group at New York University devised the ABCD acronym ( A symmetry, B order irregularity, C olor variegation, D iameter >6 mm).
That study demonstrated that most early melanomas demonstrate the following features:
A symmetry – they generally cannot be easily divided in half and have one half look like the other ( Fig. 25.1 ).
B order irregularity – the borders of most early melanomas are irregularly shaped ( Fig. 25.2 ).
C olor variability – most early melanomas have a play in color ranging from subtle nuances of tans and browns, to areas of black, and, more rarely, red, white (regression) and blue (deeper pigment) ( Fig. 25.3 ). Keep in mind, most amelanotic melanomas will lack the play in color usually seen in pigmented melanomas. Sometimes, however, there may be some subtle pigmentation within the lesion which helps the observer in making a diagnosis.
D iameter – most early melanomas when they are clinically readily identified are >6 mm in diameter ( Fig. 25.4 ).
It is important to remember that all melanomas have a microscopic origin of one or more neoplastic melanocytes. For this reason, there is a stage in the early evolution of melanoma where one or more of the ABCD criteria may be lacking. The most common missing criterion will be the D, in that a few melanomas will have diameters 6 mm or less. Therefore, a good clue to an otherwise atypical pigmented lesion is remembering that malignant neoplasms change over time. Even in a smaller lesion, a change in diameter over time in the presence of other clinically atypical features should arouse the observer's index of suspicion.
The ABCD criteria were intended as a simple tool that could be implemented in daily life, a mnemonic ‘as easy as ABC’, to alert both the layperson and healthcare professionals to the clinical features of early melanoma. Based on our experience evaluating patients in the Melanoma Cooperative Group at New York University School of Medicine, we found that asymmetry, border irregularity, and color variegation were consistently associated with lesion diameter greater than 6 mm in early melanoma lesions. These observations led to the addition of D to the A, B and C criteria. Recent studies have reconfirmed that this diameter guideline of larger than 6 mm remains a useful parameter for clinical diagnosis.
The ABCDs were intended to help describe a subset of melanomas, namely early, thin tumors that might otherwise be confused with benign pigmented lesions. Therefore, both elevated and ulcerated lesions were excluded in the initial analysis because we sought to elucidate features of early melanoma. Pigmented skin lesions that were ulcerated without a history of antecedent trauma would have already been highly suspicious for advanced melanoma and would have required biopsy regardless of other features. Also, it should be emphasized that the criteria were developed to assist non-dermatologists in differentiating common moles from cancer and were not meant to provide a comprehensive template for the recognition of all melanomas.
The ABCD criteria have subsequently been verified in multiple studies documenting their diagnostic accuracy in clinical practice. The sensitivity and specificity of these criteria vary when used singly or in combination: sensitivity ranges from 57% to 90% and specificity from 59% to 90%. Barnhill et al. investigated interobserver variability and reported moderate but statistically significant agreement in most clinical features, including irregular borders and multiple colors, among four physician evaluators, and interrater reliability and objectivity for these criteria has been demonstrated by others. The combination of reliable sensitivity and specificity in addition to adequate interobserver concordance in the application of the ABCD criteria supports the ongoing utility of this screening instrument in clinical medicine.
The importance of lesion evolution as a cardinal feature of cutaneous melanoma is also well supported. The need to recognize lesion change in our acronym was met by our revising the ABCDs through the addition of ‘E’ for ‘ E volving’. This substantially enhanced the ability of physicians and laypersons to recognize melanomas at earlier stages. ‘E’ for Evolving is especially important for the diagnosis of nodular melanomas, which frequently present as smaller lesions that are at more advanced stages (i.e. thicker tumors) where early recognition is even more critical. The ABCDE is a simple, succinct, and memorable tool, which has been demonstrated to effectively educate the public, the non-dermatologist as well as the dermatology medical community about the key features of melanoma including lesion change.
These now well-known parameters of Asymmetry, Border irregularity, Color variegation, Diameter greater than 6 mm and Evolving have been used worldwide by groups such as the American Cancer Society, American Academy of Dermatology, and others, and have been featured in the lay press to provide simple parameters for evaluation and identification of pigmented lesions that may need to be further examined. It should be noted that not all melanomas have all five ABCDE features. It is the combination of features (e.g. ABC, A+C, and the like) that render cutaneous lesions most suspicious for early melanoma.
Other melanoma early diagnosis paradigms have been developed to enhance early diagnosis. The most recognized of these is the Glasgow seven-point checklist that includes three major criteria (change in size, shape, color) and four minor criteria (sensory change, diameter of 7 mm or greater, inflammation, crusting or bleeding). The Glasgow checklist has been less widely adopted than the ABCDE criteria possibly due to its greater complexity. The ‘ugly duckling’ sign is another clinical approach, in which a pigmented lesion that ‘looks different than all of its neighbors’ may be suspicious for melanoma. This sign has been shown to be sensitive for melanoma detection, even for non-dermatologists.
The clinically diagnostic features of early malignant melanoma are relatively similar regardless of anatomic site, despite current hypotheses that melanoma from different body sites may have different etiologies.
The clinician must keep in mind that while the clinical features of early melanoma to be described are generally present in most lesions, there are exceptions that need to be recognized.
The early clinical diagnosis of melanoma has its basis not only in the clinical appearance of the lesion (physical examination), but also in the history and symptomatology. Change in a pre-existing melanocytic lesion or the development of a new pigmented lesion later in life (after the age of 40) are also important features which should alert the patient to seek medical care, and the physician to use his or her skills and ancillary technologies to rule out the possibility of a melanoma. Other clinically suspicious signs seen in pigmented lesions that are suggestive for melanoma are illustrated in Table 25.2 .
Change in color – specially multiple shades of dark brown or black; red, white and blue; spread of color from the edge of the lesion into surrounding skin |
Change in size – especially sudden or continuous enlargement |
Change in shape – especially development of irregular margins |
Change in elevation – especially sudden elevation of a previously macular pigmented lesion |
Change in surface – especially scaliness, erosion, oozing, crusting, ulceration, bleeding |
Change in surrounding skin – especially redness, swelling, satellite pigmentations |
Change in sensation – especially itching, tenderness, pain |
Change in consistency – especially softening or friability |
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here